[Pharm-policy] InKine NIH grant

[love@cptech.org]

This is typical of many grants the NIH makes to for profit entities.
Jamie

http://www.stockhouse.com/news/news.asp?tick=INKP&newsid=824075
 
InKine Awarded NIH Grant to Study Novel Anti-Cancer Treatments 
7/2/01 
 

    BLUE BELL, Pa.--(BUSINESS WIRE)--July 2, 2001--InKine Pharmaceutical
Company, Inc. (Nasdaq: INKP) today announced that the Company was
awarded a one year, Phase I Small Business Technology Transfer (STTR)
grant from the National Cancer Institute. The grant, totaling
approximately $100,000 will support pre-clinical research involving the
use of peptides derived from thrombospondin as potential treatments for
metastatic cancer. The principal investigator under the grant is George
Tuszynski, Ph.D., Professor of Medicine, Surgery and Pathology at MCP
Hahnemann University and a founding scientist of InKine. Dr. Tuszynski
has already demonstrated that these peptides have potent anti-angiogenic
and anti-metastatic activity in animal models of cancer. This grant will
allow him to further this work. At the conclusion of this grant, InKine
and Dr. Tuszynski may be eligible for a multi-year Phase II STTR grant
supporting further clinical research with these same compounds. The
Phase I grant is in addition to the $1 million NIH grant awarded to Dr.
Tuszynski in April of this year.
    "We are very pleased that the National Cancer Institute has once
again recognized the importance of Dr. Tuszynski's novel work in the
field of cancer by awarding this grant," said Martin Rose, M.D., J.D.,
InKine's Executive Vice President for Research and Development. "We look
forward to potentially moving these exciting compounds into human
clinical studies." 
    InKine has the rights to all U.S. and foreign patents and patent
applications relating to the thrombospondin technology and all future
research and development of the thrombospondin technology conducted in
Dr. Tuszynski's laboratory through a license with MCP Hahnemann
University.

About InKine Pharmaceutical

    InKine Pharmaceutical Company, Inc. is a publicly traded
biopharmaceutical company focused on the diagnosis and treatment of
cancer and autoimmune diseases. The Company's development strategy is to
acquire late-stage drug candidates with short time lines to
commercialization. Support of early-stage product opportunities comes
through its university-based sponsored research. The Company's first
product, Visicol(TM), was launched in January 2001 and is the first and
only tablet purgative preparation indicated for bowel cleansing prior to
colonoscopy. InKine's portfolio also includes three late-stage product
candidates, IBStat(TM), in development for the treatment of spasm in the
colon, Hematrol(TM), in Phase III trials for the treatment of idiopathic
thrombocytopenic purpura and Colirest(TM), in pivotal clinical trials
for the treatment of Crohn's disease. In addition, the Company is
developing preclinical compounds from its two platform technologies,
including Angiocidin(TM), a potent and specific angiogenesis inhibitor
for potential use in cancer patients, and related compounds. For further
information, please visit InKine on their web site
http://www.inkine.com.